These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21296388)

  • 41. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of a second transurethral resection for T1 bladder cancer.
    Schwaibold HE; Sivalingam S; May F; Hartung R
    BJU Int; 2006 Jun; 97(6):1199-201. PubMed ID: 16566814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer.
    Yoo JH; Suh B; Park TS; Shin MG; Choi YD; Lee CH; Choi JR
    Cancer Genet Cytogenet; 2010 Apr; 198(2):107-17. PubMed ID: 20362225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.
    Mengual L; Marín-Aguilera M; Ribal MJ; Burset M; Villavicencio H; Oliver A; Alcaraz A
    Eur Urol; 2007 Sep; 52(3):752-9. PubMed ID: 17379395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma.
    Luo B; Li W; Deng CH; Zheng FF; Sun XZ; Wang DH; Dai YP
    Cancer Genet Cytogenet; 2009 Mar; 189(2):93-7. PubMed ID: 19215789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
    Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L
    Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma.
    Youssef RF; Shariat SF; Lotan Y; Wood CG; Sagalowsky AI; Zigeuner R; Langner C; Montorsi F; Bolenz C; Margulis V
    Urology; 2011 Apr; 77(4):861-6. PubMed ID: 21167566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection.
    Wasco MJ; Daignault S; Zhang Y; Kunju LP; Kinnaman M; Braun T; Lee CT; Shah RB
    Urology; 2007 Jul; 70(1):69-74. PubMed ID: 17656211
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Fluorescent cystoscopy and transurethral electroresection in diagnosis and treatment of patients with invasive cancer of the urinary bladder].
    Komiakov BK; Gorelov SI; Novikov AI; Gorelov AI; Novikov PB; Strokova LA; Al-Atar T
    Urologiia; 2004; (6):37-40. PubMed ID: 15719729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature.
    Han KS; Joung JY; Cho KS; Seo HK; Chung J; Park WS; Lee KH
    J Endourol; 2008 Dec; 22(12):2699-704. PubMed ID: 19025393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is repeat transurethral resection effective and necessary in patients with T1 bladder carcinoma?
    Yucel M; Hatipoglu NK; Atakanli C; Yalcinkaya S; Dedekarginoglu G; Saracoglu U; Aras E
    Urol Int; 2010; 85(3):276-80. PubMed ID: 20733272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer].
    Matveev BP; Kudashev BV; Bukharkin BV; Romanov VA; Rubanov IuV
    Urologiia; 2000; (3):22-4. PubMed ID: 11186703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Two cases of vesical nephrogenic adenoma].
    Tsurukawa H; Komura H; Sasaki H; Iuchi H; Tokumitsu M; Saga Y; Yamaguchi S; Hashimoto H; Yachiku S
    Hinyokika Kiyo; 2003 May; 49(5):285-90. PubMed ID: 12822459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
    Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
    Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.
    Lee SE; Jeong IG; Ku JH; Kwak C; Lee E; Jeong JS
    Urology; 2004 May; 63(5):873-7; discussion 877. PubMed ID: 15134968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
    Isbarn H; Karakiewicz PI; Shariat SF; Capitanio U; Palapattu GS; Sagalowsky AI; Lotan Y; Schoenberg MP; Amiel GE; Lerner SP; Sonpavde G
    J Urol; 2009 Aug; 182(2):459-65; discussion 465. PubMed ID: 19524971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.